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Introduction
Infection with severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2), also known as 
coronavirus disease (COVID-19), has been classi-
fied by the World Health Organization (WHO) as an 
ongoing pandemic. Owing to the global emergency, 
there is an unmet need to identify effective and 
scalable therapeutic options to attenuate the early 
stages of virus infection. 
SARS-CoV-2 has different stages of the in-
fection cycle. The first phase is characterized by 
infection and replication of the virus within the host 
cells. The last phase occurs with cytokine storm 
leading to cellular apoptosis [1]. 
We posit the rationale for ion channel inhibi-
tion as a novel therapeutic target to counteract 
SARS-CoV-2 infection and replication. Within 
this framework, we discuss the potential clinical 
role of the ion channel inhibitors amiodarone and 
verapamil against COVID-19 that deserves clinical 
investigations. 
Mechanisms of SARS-CoV-2  
entrance into the host cell
SARS-CoV-2 belongs to the family of Coro-
naviridae, which also includes severe acute res-
piratory syndrome coronavirus (SARS-CoV) and 
middle east respiratory syndrome coronavirus 
(MERS-CoV). SARS-CoV-2 is highly contagious 
and is transmitted primarily via respiratory drop-
lets. 
A critical step in the life cycle of SARS-CoV-2 
cell entry is the binding of viral spike protein 
(S protein) subunit S1 to angiotensin converting 
enzyme 2 (ACE2) receptors that are expressed 
mainly in human alveolar cells, and protein S 
priming by host proteases. This process leads to 
fragmentation in the S1 and S2 subunit interface 
and catalyzes a membrane fusion reaction [2]. The 
S2 subunit in turn promotes the fusion of the viral 
envelope with the host cell membrane [2]. Trans-
membrane protease, serine 2 (TMPRSS2) cleaves 
and activates the viral spike glycoproteins, which 
in turn facilitates virus-cell membrane fusion. 
The conformational modification of viral en-
velope with S protein exposure and fusion with 
host cell membrane constitute the initial phase of 
cell entry.
The spike protein therefore plays a dual role 
in promoting virus entry by mediating receptor 
binding and then membrane fusion. This phase 
can be termed “early-entry” of the virus infection. 
In the absence of exogenous or membrane-
bound proteases that enable entry within the 
plasma membrane surface, coronaviruses can be 
internalized via clathrin- and non-clathrin-mediated 
endocytosis [3], where the S protein is cleaved by 
cathepsin L, which promotes fusion of viral mate-
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rial with endosomal membranes (“late entry”). 
The final common step is the release of the viral 
genome into cytoplasm and the subsequent replica-
tion of the virus.
These entry mechanisms are shared by the 
new SARS-CoV-2 with the other members of 
coronavirus family. Fusion peptides of SARS-CoV 
and SARS-CoV-2 have been found highly compa-
rable sharing more than 90% homologies in their 
biological sequences. 
Ion channels are multi-subunit, pore-forming 
membrane proteins that mediate the rapid and se-
lective passage of ions across all cell membranes. 
The underlying hypothesis is that SARS- 
-CoV-2 virion entry, host-membrane fusion and 
the ensuing virus replication in the host cells are 
governed by ion currents. Within this framework, 
Ca2+ ions are necessary to promote fusion peptide 
insertion into the lipid bilayer and the endocyto-
sis pathway (Fig. 1). Pharmacological agents that 
Figure 1. COVID-19 mechanisms of entry. COVID-19 entrance into the host cell takes place in two phases: ”early 
entry” and ”late entry”. In the “early entry” the viral S protein-subunit S1 binds the angiotensin converting enzyme 
2-receptors (ACE2-receptors) on human cells and transmembrane protease-serine 2 (TMPRSS2) facilitates virus-cell 
membrane fusion. The Ca2+ ions promote viral membrane fusion and S protein conformational changes which allow 
the fusion peptide insertion into the lipid bilayer. In the “late entry” COVID-19 is endocytosed and Ca2+ ions have an 
important role in endocytic vesicles maturation. This process ends with the release of the viral genome into cytoplasm 
and the subsequent replication of the virus. Amiodarone and verapamil block Ca2+ cell membrane and endosomal/ 
/lysosomal channels interfering with the life-cycle of coronavirus; RNA — ribonucleic acid; S protein — spike protein; 
S1-S2 — subunit 1 and subunit 2 of S protein; ER — endosplamic reticulum.
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target ion channels may therefore modulate virus 
life cycles.
Ion channel regulation of virus life cycle
Early cell entry
A role of Ca2+ in viral membrane entry and fu-
sion has been reported. Proteolytic cleavage of the 
S protein exposes its fusion peptide and initiates 
membrane fusion. It has been shown that Ca2+ plays 
an active role in stimulating the fusogenic activity 
of the SARS-CoV fusion peptide via a Ca2+ binding 
pocket [4]. Other experiments have tested the abil-
ity of virus pseudo-particles to mediate infection of 
host cells without and with Ca2+ and have shown 
that intracellular Ca2+ enhances MERS-CoV infec-
tion by approximately two-fold [5]. 
Infectivity assays with pseudoparticles ex-
pressing SARS-CoV and MERS-CoV S protein 
demonstrated that SARS-CoV and MERS-CoV 
entry into host cells was reduced when intracellular 
Ca2+ was chelated [6]. SARS-CoV and MERS-CoV 
further promote virus entry triggering a process 
termed membrane ordering that induces a rear-
rangement of membrane lipid bilayer, enhanced in 
the presence of Ca2+ [7, 8].  
Together, these observations lend support to 
the hypothesis that Ca2+ plays an active role in in-
ducing viral membrane fusion. The spike proteins 
of the SARS-CoV-2 are more robust and resistant 
than previous members of the coronavirus family. 
Ca2+ ions interacting with the fusion peptide 
can induce spatial changes in S protein altering the 
fusion peptide’s structure, and interaction with the 
cell membrane, promoting infection in MERS-CoV, 
SARS-CoV and SARS-CoV-2 [7].
Endocytosis (endosome-maturation- 
-late entry) 
Endoplasmic reticulum (ER), reticulum-Golgi 
apparatus and lysosomes are vital components of the 
host cell machinery used by the SARS-CoV-2 [9]. 
Spike, envelope and membrane proteins enter 
the ER, and the nucleocapsid protein is combined 
with the (+) strand genomic ribonucleic acid 
(RNA) to become a nucleoprotein complex. They 
merge into a complete virus particle in the host 
endoplasmic ER-Golgi apparatus compartment. 
Ca2+ has been found to exert major modulatory 
roles on ER and lysosomes [10]. While extracel-
lular Ca2+ is high, levels drop rapidly in the lumen 
of newly formed endocytic vesicles, due to the 
action of efflux pumps [11]. During later stages of 
endosome maturation, lysosome-late endosome 
fusion implies the release of Ca2+ from the lumen 
of endocytic organelles, which is used to mediate 
membrane fusion events at several stages on the 
endocytic pathway [12]. Such trafficking pathways 
can therefore lead to the availability of Ca2+ during 
the early entry of the coronavirus and afterwards 
during the late phase of mature endocytic vesicle 
formation.
Clinical utility of amiodarone and  
verapamil in patients with COVID-19 
Amiodarone is a benzofuran derivative, an 
anti-arrhythmic drug commonly used in a variety 
of settings and is approved for the treatment of 
ventricular arrhythmias and atrial fibrillation. As 
a class III antiarrhythmic agent, amiodarone is 
a non-selective ion channel inhibitor that blocks 
Ca2+, Na+ and K+ voltage-gated channels. Ami-
odarone binds to and then blocks Ca2-channels 
predominantly during the inactive or resting state 
associated with the suppression of Ca2-dependant 
action potentials. Verapamil is a prototypical phe-
nylalkylamine, which exerts antihypertensive, 
antiarrhythmic and antianginal effects. Verapamil se-
lectively inhibits intracellular transmembrane Ca2+ 
flow through L-type voltage-gated Ca2+ channels.
Previous studies have shown the effects of 
amiodarone on endosomal transport in SARS-
-CoV-infected cells by blocking Ca2+ channels [13]. 
Other in vitro data showed that amiodarone and 
verapamil, at concentrations routinely reached in 
human serum can, when employed clinically, act 
as a host cell-targeting agent that block filovirus 
entry [14]. These results confirmed that Ca2+ 
channel activity is required during virion entry 
processes [14]. 
Another study demonstrated that amiodar-
one interferes with the fusion of the Ebola viral 
envelope with the endosomal membrane at con-
centrations close to those found in patients treated 
for arrhythmias; an additive inhibitory effect of 
amiodarone and its pharmacologically active me-
tabolite monodesethyl amiodarone on entry into 
target cells has been noted [15].
Clinical perspectives
Modulation of host cell ion channel activity 
by viral proteins is being increasingly identified 
as an important virus–host interaction. With this 
background, an ongoing randomized clinical trial 
(clinicaltrials.gov ID: NCT04351763), will investi-
gate the role of amiodarone and verapamil to inhibit 
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ion channels in hospitalized patients with proven 
COVID-19. There is an urgent need to identify 
stable, effective and scalable therapeutic options 
against initial stages of virus infection and replica-
tion. Ion channel inhibition with the cardiovascular 
agents amiodarone and verapamil might reduce the 
severity of disease and the transmission potential 
of COVID-19.  
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